Roivant Sciences Ltd at Goldman Sachs Healthcare Conference Transcript
Great. Well, thanks to the team from Roivant that's here today. Richard Pulik, CFO; Mayukh Sukhatme, Chief Investment Officer.
Questions & Answers
And maybe just to start, we can talk about kind of a brief overview of the business and what you view as key programs that will shape the story over the next 12 to 24 months?
Sure. Yes. So for those of you who may be less familiar with Roivant as a company or a public company, a little over $7 billion in market cap, a little less than $2 billion in cash. We have a marketed product in VTAMA and a series of late stage, mid late-stage clinical programs, including a first-in-class TL1A antibody, an FcRn portfolio via Immunovant, a TYK2 JAK1, and many, many other things.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
